by Barry101 | Jun 17, 2019 | Press Release
OCALA, Fla., June 17, 2019 — Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s ability to reprogram tumor microenvironments and increase the effectiveness of...
by Barry101 | Jun 12, 2019 | Press Release
OCALA, Fla., June 12, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer program at the University of Pittsburgh Medical Center (UPMC) (See:...
by Barry101 | May 31, 2019 | Press Release
OCALA, Fla., May 31, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, today announced that its stockholders...
by Barry101 | May 16, 2019 | Press Release
OCALA Fla., May 16, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces financial results for the...
by Barry101 | May 13, 2019 | Press Release
OCALA, Fla., May 13, 2019 — Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announced progress toward the opening...
by Barry101 | May 8, 2019 | Press Release
OCALA, Fla., May 08, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc.’s CEO Thomas K. Equels will be attending the 2019 Celebration of Biotechnology where he’ll meet with investors and industry representatives to discuss the...
